US biopharmaceutical company Pfizer Inc (NYSE:PFE) and its German partner BioNTech SE (Nasdaq:BNTX) said on Monday that a third shot of their COVID-19 vaccine has been shown to be effective in young children.
In a Phase 2/3 trial which took place at a time when Omicron was the predominant variant, vaccine efficacy was 80.3% in children aged 6 months to under 5 years of age.
A total of 1,678 children took part in the trial, receiving a third shot of the low-dose formulation at least two months after their second shot.
Pfizer and BioNTech plan to submit the new data to the US Food and Drug Administration (FDA) this week, with submissions to the European Medicines Agency (EMA) and other regulators to follow.
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
MaaT Pharma receives negative CHMP trend vote for MaaT013
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart